RESUMO
OBJECTIVE: Research data demonstrating nutritional habits of functional dyspepsia (FD) patients are very limited. This is the first study to evaluate nutritional habits in FD subgroups according to Rome III criteria. Our aim was to evaluate nutritional habits of FD patients and determine the food items that may provoke a dyspepsia symptom. METHODS: A total of 168 adults with FD and 135 healthy control subjects participated in the study. FD subjects were divided into epigastric pain syndrome (EP-FD), postprandial distress syndrome (PS-FD), mixed (MX-FD) subgroups according to Rome Criteria III. Subjects completed a questionnaire that included a short-form food frequency questionnaire. Furthermore, subjects were asked to list the food items that were causing a dyspepsia symptom. RESULTS: Functional dyspepsia subjects had a slightly higher BMI (26.1 ± 4.97 kg/m(2)) than control subjects (24.6 ± 4.08 kg/m(2)). The most common symptom triggering foods among all the FD groups were fried and fatty foods (27.1%), hot spices (26.4%), and carbonated drinks (21.8%). In FD subgroups, carbonated drinks were more likely to cause a symptom in PS-FD group (37.3%) than MX-FD (25.7%) and EP-FD (22.1%) groups. There was no difference in frequency of main meals and snacks among any of the groups. CONCLUSION: Fatty and spicy foods and carbonated drinks were the most common symptom triggering food items in FD group. In subgroups, carbonated drinks and legumes were more likely to cause a symptom in PS-FD. Removing these food items during the course of treatment might help alleviate the symptoms.
Assuntos
Dieta , Dispepsia/etiologia , Adolescente , Adulto , Idoso , Dispepsia/classificação , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Inquéritos e Questionários , Adulto JovemAssuntos
Budesonida/uso terapêutico , Doenças do Colo/tratamento farmacológico , Diarreia/tratamento farmacológico , Glucocorticoides/uso terapêutico , Malacoplasia/tratamento farmacológico , Colo/diagnóstico por imagem , Colo/patologia , Doenças do Colo/complicações , Doenças do Colo/diagnóstico , Doenças do Colo/imunologia , Colonoscopia , Diarreia/etiologia , Feminino , Rejeição de Enxerto/imunologia , Rejeição de Enxerto/prevenção & controle , Humanos , Hospedeiro Imunocomprometido , Imunossupressores/efeitos adversos , Transplante de Rim/efeitos adversos , Malacoplasia/complicações , Malacoplasia/diagnóstico , Malacoplasia/imunologia , Pessoa de Meia-Idade , Resultado do TratamentoRESUMO
AIM: To analyze the risk factors of lamivudine treatment failure (LTF) for the long-term use in patients with low viral load (LVL). MATERIAL AND METHODS: In this multicenter study, 548 antiviral naïve noncirrhotic adult patients with LVL (for HBeAg+ patients HBV DNA <10 9 copies/ml and for HBeAgpatients HBV DNA <10 7 copies/ml) were enrolled. As a control group, 46 lamivudine-initiated patients with high viral load (HVL) were included. Primary outcome was switching to or adding on another antiviral drug as a consequence of primary nonresponse, partial response, viral breakthrough or adverse events. Secondary outcomes included LTF rates at 1, 2, 3, 4 and 5 years and LTF-related viral and host factors. RESULTS: Among 594 patients, 294 had to change lamivudine at the follow-up. Primary nonresponse, partial response, viral breakthrough or adverse events frequencies were 6.8, 1.6, 64.5 and 0.1%, respectively. Five-year LTF rates were 61.3 and 84.2% in patients with LVL and HVL, respectively. Among patients with LVL, patients with <100,000 copies/ml and ≥ 100,000 copies/ ml had 54.8 and 67.3% LTF rates at the end of the 5th year, respectively. Logistic regression analysis of risk factors showed HBeAg+, hepatic activity index, HBV DNA, virological response at 6 months and duration of follow-up were independent predictors for LTF (p values were 0.001, 0.008, 0.003, 0.020 and 0.003, respectively). CONCLUSION: Similar to patients with HVL, first-line lamivudine therapy is not efficient for long-term use in patients with LVL. LTF risk is so high even in the absence of worse predictive factors.
Assuntos
Antivirais/uso terapêutico , DNA Viral/sangue , Hepatite B Crônica/tratamento farmacológico , Lamivudina/uso terapêutico , Carga Viral , Adulto , Anticorpos Antivirais/sangue , Farmacorresistência Viral , Feminino , Seguimentos , Antígenos de Superfície da Hepatite B/imunologia , Antígenos E da Hepatite B/imunologia , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Risco , Índice de Gravidade de Doença , Fatores de Tempo , Falha de TratamentoAssuntos
Pólipos Adenomatosos/induzido quimicamente , Pólipos Adenomatosos/diagnóstico , Anticonvulsivantes/efeitos adversos , Transtorno Bipolar/tratamento farmacológico , Carbamazepina/efeitos adversos , Neoplasias Gástricas/induzido quimicamente , Neoplasias Gástricas/diagnóstico , Ácido Valproico/efeitos adversos , Pólipos Adenomatosos/terapia , Anticonvulsivantes/administração & dosagem , Carbamazepina/administração & dosagem , Esquema de Medicação , Feminino , Humanos , Pessoa de Meia-Idade , Neoplasias Gástricas/terapia , Ácido Valproico/administração & dosagemAssuntos
Colite/diagnóstico , Colite/etiologia , Colonoscopia/efeitos adversos , Fosfatos/efeitos adversos , Doença Aguda , Colite/tratamento farmacológico , Colonoscopia/métodos , Enema/efeitos adversos , Feminino , Seguimentos , Humanos , Pessoa de Meia-Idade , Fosfatos/administração & dosagem , Medição de Risco , Índice de Gravidade de Doença , Irrigação Terapêutica/efeitos adversos , Resultado do TratamentoRESUMO
BACKGROUND: Acute myeloid leukemia (AML) can develop secondary to drug treatment. This phenomenon has been placed under the title "Therapy Related Acute Myeloid Leukemias and Myelodysplastic Syndromes" in the WHO classification of AML. Cyclophosphamide, which is used in various malignancies and rheumatological diseases, is an alkylating agent that plays a significant role in therapy related AML. CASE DESCRIPTION: A patient treated with cyclophosphamide due to vasculitis, subsequently developed AML months after treatment. CONCLUSION: Cyclophosphamide related AML is seen, in most cases, many years after exposure to the drug. The significance of this report lies in the fact that, to our knowledge, this is the most rapidly arising case of cyclophosphamide related AML.